PHILADELPHIA--(BUSINESS WIRE)--June 27, 2006--Hemispherx Biopharma, Inc. (AMEX: HEB - News) announced today that Mr. Richard Piani, Lead Director on the Board of Hemispherx, will be presenting at the First International Conference on Avian Influenza in Humans at the Pasteur Institute in Paris, France, June 29 and 30. The findings being presented provide new evidence that the Company’s Alferon LDO (Low Dose Oral), a new delivery form of an anti-viral with prior regulatory approval for a category of sexually transmitted diseases, has significant potential in resisting the spread of avian influenza by stimulating genes that induce the production of immune compounds which are key building blocks in the body’s defense system.
